Apolipoprotein E synthesized by adipocyte and apolipoprotein E carried on lipoproteins modulate adipocyte triglyceride content

Lipids in Health and Disease

Ling Liu¹  Yan-hong Li¹ 

[1] Department of Cardiology, the Second Xiangya Hospital, Central South University, #139 Middle Renmin Road, Changsha, Hunan 410011, PR China

关键词: Receptor-mediated endocytosis;    Triglyceride;    Adipocyte;    Apolipoprotein E;   

Others  :  1214190
DOI  :  10.1186/1476-511X-13-136

 received in 2014-05-18, accepted in 2014-08-18,  发布年份 2014

【 摘 要 】

Excessive energy storage of adipose tissue makes contribution to the occurrence and progression of obesity, which accompanies with multiple adverse complications, such as metabolic syndrome, cardiovascular diseases. It is well known that apolipoprotein E, as a component of lipoproteins, performs a key role in maintaining plasma lipoproteins homeostasis. Interestingly, apolipoprotein E is highly expressed in adipocyte and has positive relation with body fat mass. Apolipoprotein E knock-out mice show small fat mass compared to wild type mice. Moreover, adipocyte deficiency in apolipoprotein E shows impaired lipoproeteins internalization and triglyceride accumulation. Apolipopreotein E-deficient lipoproteins can not induce preadipocyte to form round full-lipid adipocyte, whereas apolipoprotein E-containing lipoproteins can. This article mainly reviews the modulation of apolipoprotein E synthesized by adipocyte and apolipoprotein E carried on lipoproteins in adipocyte triglyceride content.

【 授权许可】

   
2014 Li and Liu; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Berghofer A, Pischon T, Reinhold T, Apovian CM, Sharma AM, Willich SN: Obesity prevalence from a European perspective: a systematic review. BMC Public Health 2008, 8:200.
• [2]Obesity: preventing and managing the global epidemic. Report of a WHO consultation World Health Organ Tech Rep Ser 2000, 894:1-253. i-xii
• [3]Shoelson SE, Herrero L, Naaz A: Obesity, inflammation, and insulin resistance. Gastroenterology 2007, 132(6):2169-2180.
• [4]Rega-Kaun G, Kaun C, Wojta J: More than a simple storage organ: adipose tissue as a source of adipokines involved in cardiovascular disease. Thromb Haemost 2013, 110(4):641-650.
• [5]Kurth T, Gaziano JM, Berger K, Kase CS, Rexrode KM, Cook NR, Buring JE, Manson JE: Body mass index and the risk of stroke in men. Arch Intern Med 2002, 162(22):2557-2562.
• [6]Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003, 348(17):1625-1638.
• [7]Atlantis E, Ball K: Association between weight perception and psychological distress. Int J Obes (Lond) 2008, 32(4):715-721.
• [8]Unger RH, Scherer PE: Gluttony, sloth and the metabolic syndrome: a roadmap to lipotoxicity. Trends Endocrinol Metab 2010, 21(6):345-352.
• [9]Hausman DB, DiGirolamo M, Bartness TJ, Hausman GJ, Martin RJ: The biology of white adipocyte proliferation. Obes Rev 2001, 2(4):239-254.
• [10]McLean JW, Elshourbagy NA, Chang DJ, Mahley RW, Taylor JM: Human apolipoprotein E mRNA. cDNA cloning and nucleotide sequencing of a new variant. J Biol Chem 1984, 259(10):6498-6504.
• [11]Kraft HG, Menzel HJ, Hoppichler F, Vogel W, Utermann G: Changes of genetic apolipoprotein phenotypes caused by liver transplantation. Implications for apolipoprotein synthesis. J Clin Invest 1989, 83(1):137-142.
• [12]Driscoll DM, Getz GS: Extrahepatic synthesis of apolipoprotein E. J Lipid Res 1984, 25(12):1368-1379.
• [13]Zechner R, Moser R, Newman TC, Fried SK, Breslow JL: Apolipoprotein E gene expression in mouse 3 T3-L1 adipocytes and human adipose tissue and its regulation by differentiation and lipid content. J Biol Chem 1991, 266(16):10583-10588.
• [14]Huang ZH, Reardon CA, Mazzone T: Endogenous ApoE expression modulates adipocyte triglyceride content and turnover. Diabetes 2006, 55(12):3394-3402.
• [15]Huang ZH, Gu D, Mazzone T: Role of adipocyte-derived apoE in modulating adipocyte size, lipid metabolism, and gene expression in vivo. Am J Physiol Endocrinol Metab 2009, 296(5):E1110-E1119.
• [16]Huang ZH, Minshall RD, Mazzone T: Mechanism for endogenously expressed ApoE modulation of adipocyte very low density lipoprotein metabolism: role in endocytic and lipase-mediated metabolic pathways. J Biol Chem 2009, 284(46):31512-31522.
• [17]Chiba T, Nakazawa T, Yui K, Kaneko E, Shimokado K: VLDL induces adipocyte differentiation in ApoE-dependent manner. Arterioscler Thromb Vasc Biol 2003, 23(8):1423-1429.
• [18]Zeljko HM, Skaric-Juric T, Narancic NS, Tomas Z, Baresic A, Salihovic MP, Starcevic B, Janicijevic B: E2 allele of the apolipoprotein E gene polymorphism is predictive for obesity status in Roma minority population of Croatia. Lipids Health Dis 2011, 10:9.
• [19]Zarkesh M, Daneshpour MS, Faam B, Hedayati M, Azizi F: Is there any association of apolipoprotein E gene polymorphism with obesity status and lipid profiles? Tehran Lipid and Glucose Study (TLGS). Gene 2012, 509(2):282-285.
• [20]Zhang J, Xuemei Z, Fan P, Liu R, Huang Y, Liang S, Liu Y, Wu Y, Bai H: Distribution and effect of apo E genotype on plasma lipid and apolipoprotein profiles in overweight/obese and nonobese Chinese subjects. J Clin Lab Anal 2012, 26(3):200-205.
• [21]Shore VG, Shore B: Heterogeneity of human plasma very low density lipoproteins. Separation of species differing in protein components. Biochemistry 1973, 12(3):502-507.
• [22]Mahley RW, Rall SC Jr: Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000, 1:507-537.
• [23]Kypreos KE, Karagiannides I, Fotiadou EH, Karavia EA, Brinkmeier MS, Giakoumi SM, Tsompanidi EM: Mechanisms of obesity and related pathologies: role of apolipoprotein E in the development of obesity. FEBS J 2009, 276(20):5720-5728.
• [24]Heeren J, Beisiegel U, Grewal T: Apolipoprotein E recycling: implications for dyslipidemia and atherosclerosis. Arterioscler Thromb Vasc Biol 2006, 26(3):442-448.
• [25]Laatsch A, Panteli M, Sornsakrin M, Hoffzimmer B, Grewal T, Heeren J: Low density lipoprotein receptor-related protein 1 dependent endosomal trapping and recycling of apolipoprotein E. PLoS One 2012, 7(1):e29385.
• [26]Strickland DK, Gonias SL, Argraves WS: Diverse roles for the LDL receptor family. Trends Endocrinol Metab 2002, 13(2):66-74.
• [27]Gonzales JC, Gordts PL, Foley EM, Esko JD: Apolipoproteins E and AV mediate lipoprotein clearance by hepatic proteoglycans. J Clin Invest 2013, 123(6):2742-2751.
• [28]Foley EM, Gordts PL, Stanford KI, Gonzales JC, Lawrence R, Stoddard N, Esko JD: Hepatic remnant lipoprotein clearance by heparan sulfate proteoglycans and low-density lipoprotein receptors depend on dietary conditions in mice. Arterioscler Thromb Vasc Biol 2013, 33(9):2065-2074.
• [29]Chen K, Williams KJ: Molecular mediators for raft-dependent endocytosis of syndecan-1, a highly conserved, multifunctional receptor. J Biol Chem 2013, 288(20):13988-13999.
• [30]Vasquez EC, Peotta VA, Gava AL, Pereira TM, Meyrelles SS: Cardiac and vascular phenotypes in the apolipoprotein E-deficient mouse. J Biomed Sci 2012, 19:22.
• [31]Seripa D, Matera MG, Daniele A, Bizzarro A, Rinaldi M, Gravina C, Bisceglia L, Corbo RM, Panza F, Solfrizzi V, Fazio VM, Forno GD, Masullo C, Dallapiccola B, Pilotto A: The missing ApoE allele. Ann Hum Genet 2007, 71(Pt 4):496-500.
• [32]Seripa D, D'Onofrio G, Panza F, Cascavilla L, Masullo C, Pilotto A: The genetics of the human APOE polymorphism. Rejuvenation Res 2011, 14(5):491-500.
• [33]Smelt AH: From gene to disease; apolipoprotein E2 and familial dysbetalipoproteinemia. Ned Tijdschr Geneeskd 2003, 147(4):157-159.
• [34]Eto M, Saito M: Familial type III hyperlipoproteinemia. Nihon Rinsho 2013, 71(9):1590-1594.
• [35]Bennet AM, Di Angelantonio E, Ye Z, Wensley F, Dahlin A, Ahlbom A, Keavney B, Collins R, Wiman B, de Faire U, Danesh J: Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA 2007, 298(11):1300-1311.
• [36]Gungor Z, Anuurad E, Enkhmaa B, Zhang W, Kim K, Berglund L: Apo E4 and lipoprotein-associated phospholipase A2 synergistically increase cardiovascular risk. Atherosclerosis 2012, 223(1):230-234.
• [37]Kofler BM, Miles EA, Curtis P, Armah CK, Tricon S, Grew J, Napper FL, Farrell L, Lietz G, Packard CJ, Caslake MJ, Mathers JC, Williams CM, Calder PC, Minihane AM: Apolipoprotein E genotype and the cardiovascular disease risk phenotype: impact of sex and adiposity (the FINGEN study). Atherosclerosis 2012, 221(2):467-470.
• [38]Weinstock PH, Bisgaier CL, Aalto-Setala K, Radner H, Ramakrishnan R, Levak-Frank S, Essenburg AD, Zechner R, Breslow JL: Severe hypertriglyceridemia, reduced high density lipoprotein, and neonatal death in lipoprotein lipase knockout mice. Mild hypertriglyceridemia with impaired very low density lipoprotein clearance in heterozygotes. J Clin Invest 1995, 96(6):2555-2568.
• [39]Ullrich NF, Purnell JQ, Brunzell JD: Adipose tissue fatty acid composition in humans with lipoprotein lipase deficiency. J Investig Med 2001, 49(3):273-275.
• [40]Brun LD, Gagne C, Julien P, Tremblay A, Moorjani S, Bouchard C, Lupien PJ: Familial lipoprotein lipase-activity deficiency: study of total body fatness and subcutaneous fat tissue distribution. Metabolism 1989, 38(10):1005-1009.
• [41]Weinstock PH, Levak-Frank S, Hudgins LC, Radner H, Friedman JM, Zechner R, Breslow JL: Lipoprotein lipase controls fatty acid entry into adipose tissue, but fat mass is preserved by endogenous synthesis in mice deficient in adipose tissue lipoprotein lipase. Proc Natl Acad Sci U S A 1997, 94(19):10261-10266.
• [42]Garcia-Arcos I, Hiyama Y, Drosatos K, Bharadwaj KG, Hu Y, Son NH, O'Byrne SM, Chang CL, Deckelbaum RJ, Takahashi M, Westerterp M, Obunike JC, Jiang H, Yagyu H, Blaner WS, Goldberg IJ: Adipose-specific lipoprotein lipase deficiency more profoundly affects brown than white fat biology. J Biol Chem 2013, 288(20):14046-14058.
• [43]Shachter NS: Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol 2001, 12(3):297-304.
• [44]Jong MC, Voshol PJ, Muurling M, Dahlmans VE, Romijn JA, Pijl H, Havekes LM: Protection from obesity and insulin resistance in mice overexpressing human apolipoprotein C1. Diabetes 2001, 50(12):2779-2785.
• [45]Goudriaan JR, Tacken PJ, Dahlmans VE, Gijbels MJ, van Dijk KW, Havekes LM, Jong MC: Protection from obesity in mice lacking the VLDL receptor. Arterioscler Thromb Vasc Biol 2001, 21(9):1488-1493.
• [46]Hofmann SM, Zhou L, Perez-Tilve D, Greer T, Grant E, Wancata L, Thomas A, Pfluger PT, Basford JE, Gilham D, Herz J, Tschöp MH, Hui DY: Adipocyte LDL receptor-related protein-1 expression modulates postprandial lipid transport and glucose homeostasis in mice. J Clin Invest 2007, 117(11):3271-3282.
• [47]Boycott KM, Flavelle S, Bureau A, Glass HC, Fujiwara TM, Wirrell E, Davey K, Chudley AE, Scott JN, McLeod DR, Parboosingh JS: Homozygous deletion of the very low density lipoprotein receptor gene causes autosomal recessive cerebellar hypoplasia with cerebral gyral simplification. Am J Hum Genet 2005, 77(3):477-483.
• [48]Gao J, Katagiri H, Ishigaki Y, Yamada T, Ogihara T, Imai J, Uno K, Hasegawa Y, Kanzaki M, Yamamoto TT, Ishibashi S, Oka Y: Involvement of apolipoprotein E in excess fat accumulation and insulin resistance. Diabetes 2007, 56(1):24-33.
• [49]Hofmann SM, Perez-Tilve D, Greer TM, Coburn BA, Grant E, Basford JE, Tschop MH, Hui DY: Defective lipid delivery modulates glucose tolerance and metabolic response to diet in apolipoprotein E-deficient mice. Diabetes 2008, 57(1):5-12.
• [50]Ewart MA, Kennedy S, Macmillan D, Raja AL, Watt IM, Currie S: Altered vascular smooth muscle function in the ApoE knockout mouse during the progression of atherosclerosis. Atherosclerosis 2014, 234(1):154-161.
• [51]Vasquez EC, Peotta VA, Meyrelles SS: Cardiovascular autonomic imbalance and baroreflex dysfunction in the apolipoprotein E-deficient mouse. Cell Physiol Biochem 2012, 29(5–6):635-646.
• [52]Duman BS, Ozturk M, Yilmazer S, Hatemi H: Apolipoprotein E polymorphism in Turkish subjects with Type 2 diabetes mellitus: allele frequency and relation to serum lipid concentrations. Diabetes Nutr Metab 2004, 17(5):267-274.
• [53]Kuhel DG, Konaniah ES, Basford JE, McVey C, Goodin CT, Chatterjee TK, Weintraub NL, Hui DY: Apolipoprotein E2 accentuates postprandial inflammation and diet-induced obesity to promote hyperinsulinemia in mice. Diabetes 2013, 62(2):382-391.
• [54]Sullivan PM, Mezdour H, Quarfordt SH, Maeda N: Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2. J Clin Invest 1998, 102(1):130-135.
• [55]Arbones-Mainar JM, Johnson LA, Altenburg MK, Maeda N: Differential modulation of diet-induced obesity and adipocyte functionality by human apolipoprotein E3 and E4 in mice. Int J Obes (Lond) 2008, 32(10):1595-1605.
• [56]Prawitt J, Niemeier A, Kassem M, Beisiegel U, Heeren J: Characterization of lipid metabolism in insulin-sensitive adipocytes differentiated from immortalized human mesenchymal stem cells. Exp Cell Res 2008, 314(4):814-824.
• [57]Lefterova MI, Lazar MA: New developments in adipogenesis. Trends Endocrinol Metab 2009, 20(3):107-114.
• [58]Yue L, Rasouli N, Ranganathan G, Kern PA, Mazzone T: Divergent effects of peroxisome proliferator-activated receptor gamma agonists and tumor necrosis factor alpha on adipocyte ApoE expression. J Biol Chem 2004, 279(46):47626-47632.
• [59]Ost A, Ortegren U, Gustavsson J, Nystrom FH, Stralfors P: Triacylglycerol is synthesized in a specific subclass of caveolae in primary adipocytes. J Biol Chem 2005, 280(1):5-8.
• [60]Fan JY, Carpentier JL, van Obberghen E, Grunfeld C, Gorden P, Orci L: Morphological changes of the 3 T3-L1 fibroblast plasma membrane upon differentiation to the adipocyte form. J Cell Sci 1983, 61:219-230.
• [61]Rothberg KG, Heuser JE, Donzell WC, Ying YS, Glenney JR, Anderson RG: Caveolin, a protein component of caveolae membrane coats. Cell 1992, 68(4):673-682.
• [62]Razani B, Combs TP, Wang XB, Frank PG, Park DS, Russell RG, Li M, Tang B, Jelicks LA, Scherer PE, Lisanti MP: Caveolin-1-deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities. J Biol Chem 2002, 277(10):8635-8647.
• [63]Yue L, Mazzone T: Endogenous adipocyte apolipoprotein E is colocalized with caveolin at the adipocyte plasma membrane. J Lipid Res 2011, 52(3):489-498.
• [64]Tao H, Aakula S, Abumrad NN, Hajri T: Peroxisome proliferator-activated receptor-gamma regulates the expression and function of very-low-density lipoprotein receptor. Am J Physiol Endocrinol Metab 2010, 298(1):E68-E79.
• [65]Ko KW, Avramoglu RK, McLeod RS, Vukmirica J, Yao Z: The insulin-stimulated cell surface presentation of low density lipoprotein receptor-related protein in 3 T3-L1 adipocytes is sensitive to phosphatidylinositide 3-kinase inhibition. Biochemistry 2001, 40(3):752-759.
• [66]Ishibashi S, Perrey S, Chen Z, Osuga J, Shimada M, Ohashi K, Harada K, Yazaki Y, Yamada N: Role of the low density lipoprotein (LDL) receptor pathway in the metabolism of chylomicron remnants. A quantitative study in knockout mice lacking the LDL receptor, apolipoprotein E, or both. J Biol Chem 1996, 271(37):22422-22427.
• [67]MacArthur JM, Bishop JR, Stanford KI, Wang L, Bensadoun A, Witztum JL, Esko JD: Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members. J Clin Invest 2007, 117(1):153-164.
• [68]Wilsie LC, Chanchani S, Navaratna D, Orlando RA: Cell surface heparan sulfate proteoglycans contribute to intracellular lipid accumulation in adipocytes. Lipids Health Dis 2005, 4:2.
• [69]Ji ZS, Pitas RE, Mahley RW: Differential cellular accumulation/retention of apolipoprotein E mediated by cell surface heparan sulfate proteoglycans. Apolipoproteins E3 and E2 greater than e4. J Biol Chem 1998, 273(22):13452-13460.
• [70]Nabeno-Kaeriyama Y, Fukuchi Y, Hayashi S, Kimura T, Tanaka A, Naito M: Delayed postprandial metabolism of triglyceride-rich lipoproteins in obese young men compared to lean young men. Clin Chim Acta 2010, 411(21–22):1694-1699.
• [71]Choi YJ, Jo YE, Kim YK, Ahn SM, Jung SH, Kim HJ, Chung YS, Lee KW, Kim DJ: High plasma concentration of remnant lipoprotein cholesterol in obese children and adolescents. Diabetes Care 2006, 29(10):2305-2310.
• [72]Ma MF, Zhang Q, Liu L: Remnant lipoprotein induces adipogenic differentiation of rat adipose tissue-derived mesenchymal stem cells. Journal of Clinical Rehabilitative Tissue Engineering Research. Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu 2010, 14(32):5992-5996.
• [73]Ma MF, Wen T, Liu L: Remnant-like particles activate peroxisome proliferator-activated receptor gamma and induce adipogenic differentiation of human adipose mesenchymal stem cells. Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu 2011, 15(32):5945-5950.
• [74]Sattar N, Petrie JR, Jaap AJ: The atherogenic lipoprotein phenotype and vascular endothelial dysfunction. Atherosclerosis 1998, 138(2):229-235.
• [75]Goldberg IJ, Bornfeldt KE: Lipids and the endothelium: bidirectional interactions. Curr Atheroscler Rep 2013, 15(11):365.
• [76]Jagla A, Schrezenmeir J: Postprandial triglycerides and endothelial function. Exp Clin Endocrinol Diabetes 2001, 109(4):S533-S547.
• [77]Meyrelles SS, Peotta VA, Pereira TM, Vasquez EC: Endothelial dysfunction in the apolipoprotein E-deficient mouse: insights into the influence of diet, gender and aging. Lipids Health Dis 2011, 10:211.
• [78]Rutledge JC, Woo MM, Rezai AA, Curtiss LK, Goldberg IJ: Lipoprotein lipase increases lipoprotein binding to the artery wall and increases endothelial layer permeability by formation of lipolysis products. Circ Res 1997, 80(6):819-828.
• [79]Tang W, Zeve D, Suh JM, Bosnakovski D, Kyba M, Hammer RE, Tallquist MD, Graff JM: White fat progenitor cells reside in the adipose vasculature. Science 2008, 322(5901):583-586.